Celldex is a clinical-stage biotech advancing barzolvolimab through Phase 3, with R&D spending nearly doubling from $30.9M in 2024Q1 to $67.5M in 2026Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.96+5.9% vs -$1.02 | $400,000-44.6% vs $722,636 |
Q3 2026 Aug 6, 2026 | -$0.94+11.3% vs -$1.06 | $22,000-97.0% vs $734,917 |
Q2 2026 May 7, 2026 | -$1.18-2.9% vs -$1.15 | $15,000-98.1% vs $795,364 |
Q1 2026 Feb 25, 2026 | -$1.22-22.0% vs -$1.00 | $100,000-92.4% vs $1M |
HAMPTON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming investor conferences: The Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026 at 9:00am ET.
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Senti Biosciences (NASDAQ: SNTI - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Insider and Institutional Ownership 25.7% of Senti Biosciences
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $37.89, but opened at $36.60. Celldex Therapeutics shares last traded at $35.18, with a volume of 3,679,133 shares traded. Celldex Therapeutics News Roundup Here are the key news stories impacting Celldex Therapeutics
Celldex Therapeutics (NASDAQ: CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the primary endpoint and all key secondary endpoints, with efficacy sustained or deepening through 24 weeks.
Benchmark CLDX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Celldex Therapeutics, Inc. (CLDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $29.87 | $1.99B | -7.59 | -78.63% | -275986.61% | -52.67% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $2.88 | $711.44M | -12.98 | 22.09% | -11.85% | -35.3% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $37.26 | $1.23B | -7.84 | -43.89% | -287.84% | -37.99% | — |
Celldex Therapeutics, Inc. (CLDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Celldex Therapeutics, Inc. (CLDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 15, 2026·SEC
Jun 26, 2026·SEC
Get notified when CLDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Celldex Therapeutics, Inc. (CLDX) stock FAQ — growth, dividends, profitability & financials explained
Celldex Therapeutics, Inc. (CLDX) reported $0.1M in revenue over the trailing twelve months. Revenue was $1.5M in fiscal year 2025. That is 36% more than the $1.1M of fiscal year 1996.
Celldex Therapeutics, Inc. (CLDX) revenue fell by 95.7% over the trailing twelve months, compared with the twelve months before.
No. Celldex Therapeutics, Inc. (CLDX) reported a net loss of $309.1M over the trailing twelve months.
Celldex Therapeutics, Inc. (CLDX) had a return on equity (ROE) of -52.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Celldex Therapeutics, Inc. (CLDX) had negative free cash flow of $259.5M over the trailing twelve months.
